GenScript PrioBio and Bio Immunitas Announce Platform Collaboration
GenScript PrioBio and Bio Immunitas will work together to develop and fast track manufacturing of a novel therapeutic platform.
GenScript ProBio, a US-based contract development and manufacturing organization specializing in biologics, and Bio Immunitas, a UK-based pharmaceutical company, announced a joint collaboration on Feb. 8, 2023. The aim of this partnership is to develop and fast track manufacturing of a novel therapeutic platform for Bio Immunitas’ novel human recombinant protein (hRPP) platform.
According to a company press release, GenScript will provide investigational new drug-enabling chemicals, manufacturing, and controls services for Bio Immunitas. These are intended to accelerate the preclinical development of two recombinant protein products that will use Bio Immunitas’ hRPP platform.
“This relationship will help us realize our commitment to creating innovative, differentiated treatments for millions of patients.” said Syed Haq, CEO and chief manufacturing officer, Bio Immunitas, in the release.
“We're delighted to collaborate with Bio Immunitas to accelerate its novel therapeutic platform and expect more patients will benefit from this superior treatment.” said Brian Min, CEO, GenScript ProBio, in the release.
Source: GenScript ProBio
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
